BNTC
Benitec Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BNTC
Benitec Biopharma Inc.
A development-stage biotechnology company that developing gene therapies to treat hepatitis C and B and age-related macular degeneration
3940 Trust Way Hayward, California 94545
--
Benitec Biopharma Inc., incorporated in Delaware on November 22, 2019 and headquartered in Hayward, California, traces its origins to Benitec Limited, which was established in Australia in 1995, after completing its re-registration in the United States on April 15, 2020. It is a clinical-stage biotechnology company engaged in the development of innovative genetic drugs. The company's proprietary platform DNA-directed RNA interference (ddRNAi), which combines RNA interference with gene therapy to achieve long-term silencing of disease-associated genes and delivery of replacement genes, forms the basis of its "silencing and replacement" strategy. Benitec is developing BB-301, a candidate gene therapy for the treatment of ophthalmopharyngeal muscular dystrophy, which has received orphan drug designation in the United States and the European Union. By focusing on genetic medicine and specialized treatments, the company has a recognized position in the field of biotechnology.
Company Financials
EPS
BNTC has released its 2026 Q1 earnings. EPS was reported at -0.22, versus the expected -0.36, beating expectations. The chart below visualizes how BNTC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
